Related Experiment Video
Updated: May 30, 2025
11:53
Oral Administration of Rotenone using a Gavage and Image Analysis of Alpha-synuclein Inclusions in the Enteric Nervous System
Published on: October 26, 2010
16.9K
α-Phellandrene: A Promising Natural Remedy for Rotenone-Induced Parkinson's Disease
Ravi Kumar1, Swamita Arora1, Sanjar Alam1
1R.V. Northland Institute of Pharmacy, India.
Recent Advances in Food, Nutrition & Agriculture
|January 31, 2025
Summary
Alpha-phellandrene shows neuroprotective effects against Parkinson's Disease (PD) in a rotenone-induced rodent model. This natural compound improved motor function and reduced neuronal damage, offering potential for PD therapeutic development.
Area of Science:
- Neuroscience
- Pharmacology
- Natural Product Chemistry
Background:
- Parkinson's Disease (PD) involves progressive loss of dopaminergic neurons, leading to motor and non-motor symptoms.
- Current PD treatments offer symptomatic relief but do not halt disease progression.
- Natural compounds are being investigated for neuroprotective properties against PD.
Purpose of the Study:
- To investigate the therapeutic potential of alpha-phellandrene in a rotenone-induced Parkinson's Disease model.
- To evaluate the neuroprotective effects of alpha-phellandrene, focusing on its antioxidant, anti-inflammatory, and anti-apoptotic properties.
Main Methods:
- Rotenone was used to induce Parkinson's Disease-like symptoms in rodent models.
- Rodents received alpha-phellandrene treatment following rotenone induction.
- Biochemical analyses measured oxidative stress, inflammation, and apoptosis markers in brain tissues.
- Histopathological examinations assessed neuronal integrity.
Main Results:
- Alpha-phellandrene administration significantly improved motor function in the PD model.
- Treatment reduced rotenone-induced oxidative stress, inflammation, and apoptosis in dopaminergic neurons.
- Histopathology revealed preserved neuronal integrity in alpha-phellandrene-treated groups.
Conclusions:
- Alpha-phellandrene exhibits significant neuroprotective effects in a rotenone-induced Parkinson's Disease model.
- These findings suggest alpha-phellandrene as a potential natural therapeutic agent for PD.
- Further research is warranted to explore its mechanisms and clinical applications.
More Related Videos
Related Concept Videos
01:24Parkinson's Disease: Treatment
192
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
192
01:15Parkinson's Disease: Overview
447
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
447
01:37Neural Regulation
39.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.1K
01:29Drugs Affecting Neurotransmitter Synthesis
1.2K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.2K